ALPMF - ESSA Pharma: Why I Remain Bullish

• ESSA Pharma developed a novel mode of action drug, EPI-7386, for the treatment of metastatic castrate-resistant prostate cancer. Pre-clinical and early Ph 1 results are promising.
• ESSA's share price crashed in mid-Aug when a change in the Ph 1 trial protocol was announced, and a delay in the expected Ph 1 monotherapy trial data release. I believe the market overreacted.
• ESSA's EPI-7386 combination Ph 1/2 trial with Astellas' enzalutamide now recruiting. Combination trials with Janssen and Bayer expected to begin soon.
• ESSA has presented additional supportive evidence on EPI-7386 mode of action on the N-Terminal of the AR. Liquid biopsy collaboration (RNA & DNA analysis) with Caris to help identify more precisely which prostate cancer patients most responsive to EPI-7386.
• I remain bullish on ESSA which may be a buyout target in 2023 if EPI-7386 show promising clinical results in monotherapy and combination trials. I recently added to my position.

For further details see: